Citi’s downgrade of Baxter International (BAX), alongside a lifted recommendation from Barclays, has put the stock in focus, as investors weigh concerns around leadership uncertainty against recent performance and sector-wide valuation shifts.
See our latest analysis for Baxter International.
At a share price of US$20.31, Baxter’s recent 7 day share price return of 9.55% and 30 day share price return of 15.86% suggest short term momentum. However, the 1 year total shareholder return has declined 34.76%, pointing to a much weaker longer term experience for investors.
If this mix of short term momentum and longer term pressure has you reassessing your watchlist, it could be a good moment to scan opportunities in healthcare focused AI stocks via our screener, starting with 39 healthcare AI stocks.
With Baxter trading at US$20.31 and an estimated intrinsic discount of about 26%, yet only a modest gap to the average analyst price target, should you see value here or assume the market already reflects future growth?
Most Popular Narrative: 6% Undervalued
With Baxter trading at $20.31 against a narrative fair value of about $21.54, the gap is modest, yet the story behind that estimate is detailed and assumption heavy.
Ongoing portfolio optimization efforts, including divestitures, cost reductions, and a commitment to eliminate stranded costs by 2027, aim to streamline operations, improve efficiency, and drive net margin improvement, which should be reflected in future earnings growth.
Want to see what sits underneath that margin rebuild story? The narrative leans on measured revenue growth, a swing back to profitability, and a valuation multiple that assumes investors stay willing to back the turnaround. The interesting part is how tightly those ingredients are calibrated to arrive at that $21.54 figure.
Result: Fair Value of $21.54 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on hospital IV usage settling closer to past norms and on Baxter avoiding further quality related setbacks in infusion pumps and injectables.
Find out about the key risks to this Baxter International narrative.
Next Steps
Mixed signals like this can leave you torn, so move quickly to review the facts, weigh the concerns and potential upside, and check the 3 key rewards and 1 important warning sign
Looking for more investment ideas?
If you are reassessing Baxter, do not stop here. Use the Simply Wall Street Screener to spot fresh opportunities that fit your style before others do.
- Target potential mispricings by scanning 47 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their underlying metrics.
- Secure your income focus by reviewing 9 dividend fortresses that offer higher yields while still paying attention to balance sheet strength and payout history.
- Dial back portfolio risk by checking 63 resilient stocks with low risk scores that show more resilient risk profiles based on a broad set of financial factors.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com